

29 January 2026

[submitted electronically via: [Slegislation@rilegislature.gov](mailto:Slegislation@rilegislature.gov)]

The Honorable Susan Donovan Chair, House Committee on Health & Human Services  
State House  
82 Smith Street  
Providence, RI 02903

RE: H7075 – RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES -- THE  
MATTHEW FEDERICO DIABETIC SAFETY ACT – **SUPPORT**

Dear Chair Donovan and members of the Committee:

The following testimony was written by Spencer Donovan, a pharmacist and the Director for Legislation for the Rhode Island Society of Health-System Pharmacists. We are an organization that represents pharmacists that practice within the health care system including hospitals and ambulatory care clinics. My comments and support are representative of both my organization and myself. Thank you for allowing time to voice support for H7075.

Glucagon is a life-saving medication used to treat severe hypoglycemia (low blood sugar), a medical emergency that can lead to significant patient harm including seizures and death if not treated immediately. For patients living with diabetes affordable access to glucagon is vital to their safety and wellbeing. This bill would require health insurance plans that provide prescription coverage in Rhode Island to cover at least one type of glucagon auto-injector, nasal spray, or other formulation that does not require reconstitution to treat hypoglycemia. It would also ensure that patients can receive at least two glucagon devices per year without copayments or deductibles; most patients need more than one glucagon device per year so it can be stored in multiple locations (ex. Work and home) and be replaced when used or expired. It is important that patients have the option to access different formulations (ex. Auto-injector, nasal spray, others) as these are approved for different ages and circumstances, and their ease of administration can significantly improve effective use during emergencies.

By mandating glucagon coverage without copayments or deductibles H7075 empowers patients to obtain this life-saving medication each year and be better prepared to treat severe hypoglycemia without requiring intervention by medical professionals. This will prevent unnecessary emergency department visits, provide affordable access to essential emergency medication, and promote health equity for at-risk patients throughout Rhode Island.

We urge you to support H7075 as it will not only acknowledge the vital role of health-system pharmacists but also improve the quality of healthcare for the citizens of Rhode Island. Thank you for considering this important legislation.

Sincerely,

*Spencer Donovan*

Spencer Donovan, PharmD, MHA, DPLA

Director of Legislation, Rhode Island Society of Health-System Pharmacists